Recruiting

Observational Study

Sponsor:

M.D. Anderson Cancer Center

Code:

NCT05904782

Conditions

Cancer

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Study Details

Brief summary:

To learn more about the experience and wellbeing of people who provide care for cancer patients.

Conditions

Cancer

Study ID

NCT05904782

Start date

Aug 29, 2025

Status verified date

Aug, 2026

Completion date

Nov 1, 2027

Anticipated

Primary completion date

Nov 1, 2027

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Inclusion Criteria:

  • Provision of signed and dated informed consent form
  • Stated willingness to comply with all study procedures and availability for the duration of the study
  • Males and female adults ≥18 years
  • Able to read and speak English
  • Caregiver of a patient diagnosed with stage IV solid malignancy, with whom they have been residing for >6 months
  • Access to necessary resources for participating in a technology-based intervention (i.e., telephone, internet access)

Exclusion Criteria:

  • Current participation in consistent (self-defined) psychotherapy
  • Caregivers who are considered part of a vulnerable population (i.e. cognitively impaired (self-reported or patient-reported), pregnant, military personnel) will not be eligible.

Study Design

Enrollment

150 participants

Anticipated

Interventions and Outcome Measures

Primary outcome measure

  • Quality of Life questionnaire (Qol) [ Time Frame: through completion of study; approximately 1 month ]

Central Contacts and Locations

Central contacts

Locations

The University of Texas M. D. Anderson Cancer Center

Recruiting

Houston, Texas, United States, 77030

Contacts

Principal Investigator:

Juliet Kroll, BA, PHD

More Information

Sponsor

M.D. Anderson Cancer Center

Last update posted

Aug 14, 2026

Last verified

Aug, 2026

Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-09. This information was provided to ClinicalTrials.gov by M.D. Anderson Cancer Center on 2026-08-14.